Stay up to date on the latest in health tech, digital health and health AI news with this weekly brief. This is news from the week of July 6 to 10.
Samsung, Neuroscape partner on cognitive study
Samsung is partnering with Neuroscape to study cognitive changes across the adult lifespan, the organizations announced Thursday.
The Neuroscape Technology for Aging Health - Digital Approaches (TAH-DA) study seeks to identify biometric predictors of cognitive decline over the course of a year using Samsung’s wearables—namely the Galaxy Watch and Galaxy Tab A9. Recruitment began earlier this year, with a goal of 200 participants aged 40 to 89.
"With this rich dataset, we will be able to determine which passive, biometric measures are associated with cognitive assessments, as well as test the effects of our evidence-based, digital interventions in boosting cognitive function in adults across their lifespans," says Joaquin Anguera, Ph.D., Neuroscape director of clinical division, in a statement. “Unlike traditional neuroscience studies, which often use highly controlled, simplified stimuli and static laboratory environments, modern approaches look to study human cognition in real-world contexts and in real-time.”
Surgical Safety Technologies rebrands to procedural ambient AI platform
Surgical Safety Technologies rebranded to Aimbient, what it touts as the only procedural ambient AI platform to transform procedural environments.
Aimbient is built on more than 15 million hours of real procedural data, the largest procedural dataset in the healthcare industry, executives say. It works across operating rooms, cath labs, endoscopy suites, labor and delivery and trauma and recovery.
“We built this technology because, as surgeons, we knew we couldn't improve what we couldn't objectively measure,” said Teodor Grantcharov, M.D., Ph.D, Aimbient founder and CEO, in a statement. “What began as a way to help surgeons learn and improve has become something much bigger. Today, health systems don't just see what happened in a case; they have the intelligence to run every one better. Our vision is a world where every procedure advances the next.”
The platform is live across 450 procedural rooms in the U.S. and Europe with additional capabilities to come, according to the July 7 announcement.
UC San Diego launches applied health intelligence institute
University of California-San Diego announced Monday the launch of its Institute for Applied Health Intelligence, a new collaboration with six schools and UC San Diego Health to accelerate data-driven, equitable healthcare.
The institute is built on three strategic pillars: health intelligence and implementation leadership; training and education and innovation, outcomes and research. Its goal is to achieve “scalable, reliable health outcomes for all” with health innovations.
“In health care, the most critical gap isn’t usually a lack of innovation, but the ‘last mile’— the systemic challenge of integrating new discoveries into the daily flow of patient care,” said Patty Maysent, UC San Diego Health CEO, in a statement. “Leveraging the intelligence of this institute will enable us to reduce clinical variation and eliminate preventable harm, ensuring that we deliver the highest standard of care to every patient, every time.”
Alongside partner schools, the institute will also work with specialized centers—including the San Diego Supercomputer Center, the Sanford Institute for Empathy and Compassion and the Center for Healthcare Cybersecurity.
IVI RMA Global, Conceivable Life Sciences to deploy first AI IVF lab in 2027
Fertility care organization IVI RMA Global announced Thursday a strategic partnership with Conceivable Life Sciences to deploy the world’s first automated-assisted in vitro fertilization (IVF) laboratory system in a U.S. clinic.
Conceivable’s Aura platform is designed to work alongside embryologists through perceiving, reasoning and executing live in clinical environments. It’s currently being evaluated in ongoing pilot studies, according to the July 2 announcement, with more than 100 patients treated, more than 1,000 eggs processed and live births achieved.
Deployment of the platform will begin at an IVI RMA U.S. locations in 2027, with expansion planned across IVI RMA's network in Europe, Latin America and the Middle East.
“IVI RMA's decision to partner with Conceivable is a defining moment for reproductive medicine and it reflects something deeper than a commercial agreement,” said Alan Murray, Conceivable Life Sciences CEO and co-founder, in a statement. “Together, we have the opportunity to establish a new benchmark for IVF laboratory performance and to close the gap between the standard of care available at the world's best clinics and what more patients can actually access.”